BioSpace News Archive

JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today’s decision from the U.S Food and Drug Administration to approve Provention Bio’s Tzield™ (teplizumab-mzwv).

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share, for total gross proceeds of $50,050,000.

PaxMedica, Inc. announced that the Company has entered into a purchase agreement and registration rights agreement for up to $20 million with Lincoln Park Capital Fund, LLC.

RAPT Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 4,054,055 shares of its common stock at a price to the public of $18.50 per share.

FundaMental Pharma GmbH announces that it has launched with EUR 10 million in seed financing led by BioGeneration Ventures and Thuja Capital, with participation from other investors, including coparion and High-Tech Gründerfonds.

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced a partnership with Population Health Partners, L.P. (PHP) a global life-science firm dedicated to solving the health and economic challenges presented by prevalent diseases.

atai Life Sciences N.V. today announced it has initiated a clinical study with Massachusetts General Hospital (MGH).

Pathnostics announced the broadening of its diagnostic laboratory capabilities with the opening of its third lab, located in Lake Mary, Florida, and expansion of its Irvine, California-based laboratory and headquarters.

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, held a virtual event yesterday showcasing the Company’s latest innovation across its market-leading 360 portfolios.

Sirona Medical today announced a comprehensive distribution and collaboration partnership with RevealDX and the integration of Nines’ FDA-cleared automated measurement tool recently acquired by Sirona to improve end to end care for patients with lung nodules.